Skip to content

CMND

Clearmind Medicine, Inc.

NASDAQ · Healthcare · Biotechnology · CA

$6.00
−4.15%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
-75.7%
EBIT
-38.1%
EPS
—
Free cash flow
-26.3%
Operating cash flow
-26.3%

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
—
EBITDA
+22.4%
EBIT
+1.4%
Net income
+26.6%
EPS
+55.3%
Free cash flow
+30.0%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026